RxDoctor Payments DataLook up a doctor →

Kendall Jenson, PA

Medical · Scottsdale, AZNPI 1881706885

Payments from drug & device makers

$38,606in general payments, 2019–2025

Across 1,191 payments — averaging $32.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$6K
  • Incyte Corporation$4K
  • Sun Pharmaceutical Industries Inc.$3K
  • LEO Pharma Inc.$3K
  • AbbVie$3K
  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$3K
  • plus $17K from 27 others

What the payments were for

  • Consulting fees$13,19034%
  • Speaking & faculty fees$4,69012%
  • Travel & lodging$8792%
  • Food & beverage$19,46150%
  • Education$3871%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$38,606 in reported general payments places this provider in the 95th percentile of 748 medical providers in Arizona.

See all medical providers in Arizona

Medicare billing

Part B allowed, 2024
$135,350
Medicare patients
629
Services billed
2,132

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast34$165,384
Dupixent PenDupilumab17$68,839
Humira(Cf) PenAdalimumab11$68,352
Tacrolimus47$5,445
Clobetasol Propionate119$3,323
Ketoconazole182$3,125
Fluorouracil30$1,957
Doxycycline Hyclate72$1,702
ValacyclovirValacyclovir Hcl36$1,681
Metronidazole24$1,491
Tretinoin13$1,371
Fluticasone Propionate52$1,294
Triamcinolone Acetonide90$1,214
Clindamycin Phosphate21$962
Ciclopirox36$898

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$1,492$165,38434 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 748 medical providers in Arizona.

Other medical in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →